<DOC>
	<DOCNO>NCT00405249</DOCNO>
	<brief_summary>The purpose 28 day study assess viral kinetics safety elvucitabine .</brief_summary>
	<brief_title>Safety Study Elvucitabine HIV-1 Subjects</brief_title>
	<detailed_description>This 14 day treat/14 day treatment randomize , double blind viral kinetic study elvucitabine versus lamivudine administer daily HIV infect subject document M184V variant .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV infect , clinically stable , adult HIVRNA 5000 150,000 , CD4 100 Genotypically document M184V variant Receiving stable ART . Hep B HIV1 genotype 4 protease inhibitor HIV1 genotype positive 2 NNRTI mutation Previous therapy system myelosuppressive potential within 3 month study start Use Epogen Neupogen History cirrhosis Alcohol drug dependence Inability tolerate oral medication Women pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>